These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1692938)

  • 21. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes.
    Relling MV; Evans WE; Fonné-Pfister R; Meyer UA
    Cancer Res; 1989 Jan; 49(1):68-71. PubMed ID: 2908853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol.
    Masubuchi Y; Fujita S; Chiba M; Kagimoto N; Umeda S; Suzuki T
    Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):861-5. PubMed ID: 2009081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
    Tyndale RF; Kalow W; Inaba T
    Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
    Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
    Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
    Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
    Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
    Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
    Jaruratanasirikul S; Cooper AD; Blaschke TF
    Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
    Zanger UM; Vilbois F; Hardwick JP; Meyer UA
    Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
    Gross AS; Mikus G; Fischer C; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
    Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
    FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo.
    Manns M; Zanger U; Gerken G; Sullivan KF; Meyer zum Büschenfelde KH; Meyer UA; Eichelbaum M
    Hepatology; 1990 Jul; 12(1):127-32. PubMed ID: 2373473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.
    Fonne-Pfister R; Bargetzi MJ; Meyer UA
    Biochem Biophys Res Commun; 1987 Nov; 148(3):1144-50. PubMed ID: 3500719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes.
    Broly F; Libersa C; Lhermitte M; Dupuis B
    Biochem Pharmacol; 1990 Mar; 39(6):1045-53. PubMed ID: 2322292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients.
    Bendriss A; Bechtel Y; Paintaud G; Bendriss EK; Joanne C; Bresson-Hadni S; Magnette J; Becker MC; Gillet M; Mantion G
    Ther Drug Monit; 1995 Apr; 17(2):113-9. PubMed ID: 7624897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.